Highlights of This Issue 3717

SPECIAL FEATURES

CCR Translations

3719  
Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks  
John M.L. Ebos and Roberto Pili  
See article p. 3961

CCR Perspectives in Drug Approval

3722  
Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary  

Molecular Pathways

3743  
Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations  
Jeyanthi Eswaran, Da-Qiang Li, Anil Shah, and Rakesh Kumar

Review

3750  
Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience  
Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, and Stan B. Kaye

HUMAN CANCER BIOLOGY

3762  
Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact  
Mário Henrique M. Barros, Rocío Hassan, and Gerald Niedobitek

3772  
Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma  
Yu Sawada, Motonobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kobayashi, and Yoshiki Tokura

Statistics in Clinical Cancer Research

3780  
Cure Models as a Useful Statistical Tool for Analyzing Survival  
Megan Othus, Bart Barlogie, Michael L. LeBlanc, and John J. Crowley

CCR Drug Updates

3791  
Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target  
Leena Gandhi and Pasi A. Jänne
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3803</td>
<td>Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas</td>
<td>Luigi Scotto, Marianna Kruthof-de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, Jairo Baquero Buitrago, Jennifer Amengual, Michael M. Shen, and Owen A. O'Connor</td>
</tr>
<tr>
<td>3822</td>
<td>Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy</td>
<td>Clare McCourt, Pamela Maxwell, Roberta Mazzucchelli, Rodolfo Montironi, Marina Scarpelli, Manuel Salto-Tellez, Joe M. O'Sullivan, Daniel B. Longley, and David J.J. Waugh</td>
</tr>
<tr>
<td>3846</td>
<td>Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response</td>
<td>Harvey Wong, Edna F. Choo, Bruno Aliche, Xiao Ding, Hank Lai, Erin McNamara, Frank-Peter Theil, Jay Tibbitts, Lori S. Friedman, Cornelis E.C.A. Hop, and Stephen E. Gould</td>
</tr>
<tr>
<td>3856</td>
<td>Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206</td>
<td>Eric Sanchez, Mingjie Li, Cathy Wang, Cydney M. Nichols, Jennifer Li, Haiming Chen, and James R. Berenson</td>
</tr>
<tr>
<td>3880</td>
<td>Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression</td>
<td>Shu Feng, Longjiang Shao, Wendong Yu, Paul Gavine, and Michael Ittmann</td>
</tr>
<tr>
<td>3901</td>
<td>Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer</td>
<td>Abbas Belkhir, Shoumin Zhu, Zheng Chen, Mohammed Souotto, and Wael El-Rifai</td>
</tr>
<tr>
<td>3912</td>
<td>GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo</td>
<td>Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, and Deepak Sampath</td>
</tr>
<tr>
<td>3936</td>
<td>Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice</td>
<td>Kinya Inoue, Takuji Torimura, Toru Nakamura, Hideki Iwamoto, Hiroshi Masuda, Mitsuhiko Abe, Osamu Hashimoto, Hiroshi Koga, Takato Ueno, Hirohisa Yano, and Michio Sata</td>
</tr>
</tbody>
</table>
Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma
Jordan Madic, Sophie Piperno-Neumann, Vincent Servois, Aurore Rampanou, Maud Milder, Bénédicte Trouiller, David Gentien, Stéphanie Saada, Franck Assayag, Aurélie Thuleau, Fariba Nennati, Didier Decaudin, François-Clément Biedar, Laurence Desjardins, Pascale Mariani, Olivier Lantz, and Marc-Henri Stern

A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival
Jason A. Willis, Sara H. Olson, Irene Orlow, Semanti Mukherjee, Robert R. McWilliams, Robert C. Kurtz, and Robert J. Klein

Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier

Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients

See commentary p. 3719

Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis
Junjie Wu, Jie Liu, Yuhao Zhou, Jun Ying, Houdong Zou, Shicheng Guo, Lei Wang, Naïqing Zhao, Jianjun Hu, Daru Lu, Li Jin, Qiang Li, and Jiu-Cun Wang

Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients
Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A. Hildebrandt, Jie Lin, Maosheng Huang, George A. Calin, Dingzhi Wang, Raymond N. Dulsios, Ernest T. Hawk, and Xifeng Wu

Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy
Yu-Yun Shao, Chien-Chung Huang, Shiou-Der Lin, Chih-Hung Hsu, and Ann-Lii Cheng

Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck

CORRECTION

Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck
ABOUT THE COVER

The inhibition of androgen signaling is a major therapeutic strategy in prostate cancer; however, response is often transient, and patients ultimately relapse on therapy giving rise to a currently incurable condition known as castrate-resistant prostate cancer (CRPC). McCourt and colleagues show elevated expression of the androgen-regulated antiapoptotic protein c-FLIP in prostate cancer, which is further elevated in CRPC. Repression of c-FLIP induced apoptosis in non–castrate-resistant and CRPC cells and potentiated sensitivity to AR-targeted therapy, indicating that prostate cancer cells require c-FLIP to maintain viability. Consequently, targeting c-FLIP may represent a novel strategy to improve therapeutic response to the novel antiandrogen strategies under clinical development in CRPC. For details, see the article by McCourt and colleagues on page 3822 of this issue.